Emotion regulation and insomnia as candidate processes of change in a digital mental health intervention.

Behav Res TherJul 31, 2026 (epub)
Clinical ResearchPsychiatry

A Theurel, M A Martinie, A Fournier et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the ETUCARE digital mental health intervention among 1064 French university students, focusing on emotion regulation and insomnia as processes of change. Results indicated that ETUCARE improved emotion regulation (β = .166, p < .001) and reduced insomnia (β = -.142, p < .001), contributing to lower distress and higher well-being.

Key findings

  • ETUCARE improved emotion regulation with a β of .166 (p < .001).
  • Insomnia was reduced with a β of -.142 (p < .001).
  • Combined pathways accounted for 33.6% of the total association with distress.
  • Both emotion regulation and insomnia significantly influenced distress and well-being.

Why it matters

Understanding the mechanisms behind digital mental health interventions can enhance their effectiveness. By identifying emotion regulation and insomnia as key processes, clinicians can better tailor interventions to improve mental health outcomes.

Source

PubMed · PMID 42585724

Published in Behav Res Ther. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.